文献速递胃肠动力与功能性疾病

曲地匹坦治疗糖尿病性和特发性胃轻瘫患者的3期随机安慰剂对照临床试验疗效

The Efficacy of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Phase 3 Randomized Placebo-Controlled Clinical Trial.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-01-17

201例成人胃轻瘫患者随机接受口服曲地匹坦85 mg(n=102)或安慰剂(n=99)每日两次治疗12周。意向治疗人群未达到预设主要终点(第12周恶心严重程度变化药物与安慰剂比较,P=.741),但事后药代动力学暴露-反应分析显示高血药浓度者恶心显著改善,提示曲地匹坦对胃轻瘫恶心症状有潜在治疗作用。

要点

  • 意向治疗人群第12周恶心严重程度变化药物与安慰剂比较未达预设主要终点(P=.741)。
  • 高血药浓度曲地匹坦者在第2-4周早期即出现平均恶心严重程度显著改善。
  • 事后敏感性分析中曲地匹坦在12周时恶心改善具统计学显著性。

核心结论

  • 尽管曲地匹坦在意向治疗人群中未达统计学显著性,但药代动力学暴露-反应分析显示充分暴露时具显著效应。
  • 在控制基线严重程度膨胀和补救药物等混杂因素后,也观察到统计学显著效应。
  • 这些发现提示曲地匹坦对胃轻瘫的恶心症状具有潜在治疗作用。

研究设计与样本

  • 3期随机安慰剂对照临床试验,纳入201例成人胃轻瘫患者,随机分配至口服曲地匹坦85 mg(n=102)或安慰剂(n=99)每日两次治疗12周。
  • 通过每日症状日记、胃轻瘫主要症状指数评分及其他患者报告问卷评估症状,并监测血药浓度进行暴露-反应分析。

主要发现

  • 意向治疗人群第12周未达到预设主要终点(恶心严重程度变化药物与安慰剂比较,P=.741),也未达到预设次要终点。
  • 高血药浓度曲地匹坦受试者从第2-4周早期时间点开始平均恶心严重程度显著改善。
  • 事后敏感性分析中曲地匹坦治疗显示增强效应,第12周恶心改善具统计学显著性。

关键数值与推荐

  • 主要终点为每日症状日记测量的平均恶心严重程度从基线至第12周的变化。
  • 曲地匹坦给药方案为口服85 mg每日两次,疗程12周。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 意向治疗人群未达到预设主要终点和预设次要终点。
  • 事后分析用于控制药物暴露、补救药物和基线严重程度膨胀。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neurokinin receptor 1 antagonists are effective in reducing nausea and vomiting in chemotherapy-induced emesis. We investigated the safety and efficacy of tradipitant, a neurokinin receptor 1 antagonist, in patients with idiopathic and diabetic gastroparesis. METHODS: A total of 201 adults with gastroparesis were randomly assigned to oral tradipitant 85 mg (n = 102) or placebo (n = 99) twice daily for 12 weeks. Symptoms were assessed by a daily symptom dairy, Gastroparesis Cardinal Symptom Index scores, and other patient-reported questionnaires. Blood levels were monitored for an exposure-response analysis. The primary outcome was change from baseline to week 12 in average nausea severity, measured by daily symptom diary. RESULTS: The intention-to-treat (ITT) population did not meet the prespecified primary endpoint at week 12 (difference in nausea severity change drug vs placebo; P = .741) or prespecified secondary endpoints. Post hoc analyses were performed to control for drug exposure, rescue medications, and baseline severity inflation. Subjects with high blood levels of tradipitant significantly improved average nausea severity beginning at early time points (weeks 2-4). In post hoc sensitivity analyses, tradipitant treatment demonstrated strengthened effects, with statistically significant improvements in nausea at week 12. CONCLUSIONS: Although tradipitant did not reach significance in the ITT population, a pharmacokinetic exposure-response analysis demonstrated significant effects with adequate tradipitant exposure. When accounting for confounding factors such as baseline severity inflation and rescue medication, a statistically significant effect was also observed. These findings suggest that tradipitant has potential as a treatment for the symptom of nausea in gastroparesis. (ClincialTrials.gov, Number: NCT04028492).

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Carlin JL, Polymeropoulos C, Camilleri M, et al. The Efficacy of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Phase 3 Randomized Placebo-Controlled Clinical Trial. Clin Gastroenterol Hepatol. 2024. PMID: 38237696. doi:10.1016/j.cgh.2024.01.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。